Adaptive Biotechnologies Corp. (ADPT)
25.54
-0.45
(-1.73%)
USD |
NASDAQ |
Aug 24, 16:00
25.54
0.00 (0.00%)
After-Hours: 20:00
Adaptive Biotechnologies Enterprise Value : 4.208B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 4.208B |
| August 20, 2026 | 4.120B |
| August 19, 2026 | 4.128B |
| August 18, 2026 | 3.980B |
| August 17, 2026 | 4.014B |
| August 14, 2026 | 4.009B |
| August 13, 2026 | 3.965B |
| August 12, 2026 | 4.090B |
| August 11, 2026 | 4.113B |
| August 10, 2026 | 4.122B |
| August 07, 2026 | 4.039B |
| August 06, 2026 | 3.828B |
| August 05, 2026 | 3.987B |
| August 04, 2026 | 3.979B |
| August 03, 2026 | 3.750B |
| July 31, 2026 | 3.664B |
| July 30, 2026 | 3.920B |
| July 29, 2026 | 3.662B |
| July 28, 2026 | 3.656B |
| July 27, 2026 | 3.659B |
| July 24, 2026 | 3.616B |
| July 23, 2026 | 3.623B |
| July 22, 2026 | 3.565B |
| July 21, 2026 | 3.666B |
| July 20, 2026 | 3.551B |
| Date | Value |
|---|---|
| July 17, 2026 | 3.720B |
| July 16, 2026 | 3.589B |
| July 15, 2026 | 3.716B |
| July 14, 2026 | 3.483B |
| July 13, 2026 | 3.417B |
| July 10, 2026 | 3.424B |
| July 09, 2026 | 3.541B |
| July 08, 2026 | 3.281B |
| July 07, 2026 | 3.386B |
| July 06, 2026 | 3.494B |
| July 02, 2026 | 3.444B |
| July 01, 2026 | 3.632B |
| June 30, 2026 | 3.486B |
| June 29, 2026 | 3.415B |
| June 26, 2026 | 3.345B |
| June 25, 2026 | 3.232B |
| June 24, 2026 | 3.086B |
| June 23, 2026 | 2.749B |
| June 22, 2026 | 2.772B |
| June 18, 2026 | 2.797B |
| June 17, 2026 | 2.677B |
| June 16, 2026 | 2.748B |
| June 15, 2026 | 2.786B |
| June 12, 2026 | 2.808B |
| June 11, 2026 | 2.989B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Personalis, Inc. | 1.780B |
| 10X Genomics, Inc. | 8.011B |
| Alamar Biosciences, Inc. (California) | 2.177B |
| Champions Oncology, Inc. | 68.73M |
| Medpace Holdings, Inc. | 16.92B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -39.94M |
| Revenue (Quarterly) | 71.55M |
| Total Expenses (Quarterly) | 111.34M |
| EPS Diluted (Quarterly) | -0.2489 |
| Gross Profit Margin (Quarterly) | 70.15% |
| Profit Margin (Quarterly) | -55.82% |
| Earnings Yield | -1.60% |
| Normalized Earnings Yield | -1.171 |